Kennedy Capital Management’s Arbutus Biopharma ABUS Stock Holding History

Kennedy Capital Management’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.85M	Sell	385,298 -7,834	-2%	-$34.4K	0.03%	461
2026 Q1	$1.77M	Sell	393,132 -111,962	-22%	-$490K	0.04%	434
2025 Q4	$2.43M	Sell	505,094 -5	-0%	-$22	0.05%	401
2025 Q3	$2.29M	Buy	505,099 +55,920	+12%	+$205K	0.05%	429
2025 Q2	$1.39M	Buy	449,179 +29,842	+7%	+$99.1K	0.03%	478
2025 Q1	$1.46M	Sell	419,337 -1,372	-0.3%	-$4.58K	0.04%	466
2024 Q4	$1.38M	Buy	420,709 +804	+0.2%	+$2.96K	0.03%	562
2024 Q3	$1.62M	Sell	419,905 -37,673	-8%	-$145K	0.04%	543
2024 Q2	$1.41M	Buy	457,578 +21,072	+5%	+$63.2K	0.03%	550
2024 Q1	$1.13M	Buy	436,506 +49,265	+13%	+$128K	0.02%	611
2023 Q4	$968K	Sell	387,241 -5,602	-1%	-$11K	0.02%	588
2023 Q3	$797K	Hold	392,843	–	–	0.02%	584
2023 Q2	$904K	Hold	392,843	–	–	0.02%	561
2023 Q1	$1.19M	Buy	+392,843	New	+$1.11M	0.04%	463

Other funds holding ABUS

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

WCM

Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Kennedy Capital Management's ABUS Position: Q2 2026 in Review

Kennedy Capital Management reduced its Arbutus Biopharma (ABUS) stake by 2% in Q2 2026, selling an estimated $34.4K and leaving 385,298 shares worth $1.85M. The position accounts for 0.03% of the portfolio, ranked #461.

Kennedy Capital Management first reported a position in ABUS in Q1 2023 and has held it in 14 quarters since. The position peaked at $2.43M in Q4 2025. 177 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

Kennedy Capital Management held 385,298 shares of Arbutus Biopharma worth $1.85M as of Q2 2026.
Kennedy Capital Management sold 7,834 Arbutus Biopharma shares in Q2 2026, an estimated $34.4K.
Arbutus Biopharma made up 0.03% of Kennedy Capital Management's portfolio in Q2 2026, its #461 holding.
Kennedy Capital Management first reported a position in Arbutus Biopharma in Q1 2023 and has held it in 14 quarters since.
Kennedy Capital Management's Arbutus Biopharma position peaked at $2.43M in Q4 2025.
177 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Kennedy Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.